ES2546105T3 - Anticuerpo de reacción cruzada contra Staphylococcus aureus - Google Patents

Anticuerpo de reacción cruzada contra Staphylococcus aureus Download PDF

Info

Publication number
ES2546105T3
ES2546105T3 ES13728122.6T ES13728122T ES2546105T3 ES 2546105 T3 ES2546105 T3 ES 2546105T3 ES 13728122 T ES13728122 T ES 13728122T ES 2546105 T3 ES2546105 T3 ES 2546105T3
Authority
ES
Spain
Prior art keywords
staphylococcus aureus
cross
antibody against
against staphylococcus
reactive antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13728122.6T
Other languages
English (en)
Inventor
Eszter Nagy
Adriana BADARAU
Harald ROUHA
Lukas STULIK
Gábor Nagy
Irina MIRKINA
Zoltán MAGYARICS
Zehra VISRAM
Michaela JAEGERHOFER
Manuel Zerbs
Ivana DOLEZILKOVA
Astrid Teubenbacher
Michael Benjamin BATTLES
Bianka Dominique PRINZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
X4 Pharmaceuticals Austria GmbH
Original Assignee
Arsanis Biosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences GmbH filed Critical Arsanis Biosciences GmbH
Application granted granted Critical
Publication of ES2546105T3 publication Critical patent/ES2546105T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un anticuerpo con neutralización cruzada que neutraliza la toxina alfa (HIa) y al menos una de las toxinas de dos componentes de Staphylococcus aureus, donde el anticuerpo comprende al menos un sitio de unión poliespecífico que se une a la toxina alfa (Hla) y que se une a al menos una de las toxinas de dos componentes de Staphylococcus aureus.
ES13728122.6T 2012-04-17 2013-04-17 Anticuerpo de reacción cruzada contra Staphylococcus aureus Active ES2546105T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12164506 2012-04-17
EP12164506 2012-04-17
EP13151010 2013-01-11
EP13151010 2013-01-11
PCT/EP2013/058022 WO2013156534A1 (en) 2012-04-17 2013-04-17 Cross-reactive staphylococcus aureus antibody

Publications (1)

Publication Number Publication Date
ES2546105T3 true ES2546105T3 (es) 2015-09-18

Family

ID=48607210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13728122.6T Active ES2546105T3 (es) 2012-04-17 2013-04-17 Anticuerpo de reacción cruzada contra Staphylococcus aureus

Country Status (18)

Country Link
US (1) US9914767B2 (es)
EP (1) EP2668208B1 (es)
JP (1) JP6228186B2 (es)
CN (1) CN104640878B (es)
AU (1) AU2013251165B2 (es)
BR (1) BR112014025299A8 (es)
CA (1) CA2870223A1 (es)
DK (1) DK2668208T3 (es)
ES (1) ES2546105T3 (es)
HU (1) HUE025378T2 (es)
IL (1) IL235089B (es)
MX (1) MX355985B (es)
NZ (1) NZ700578A (es)
PL (1) PL2668208T3 (es)
PT (1) PT2668208E (es)
RU (1) RU2014145830A (es)
WO (1) WO2013156534A1 (es)
ZA (1) ZA201407330B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2999713A2 (en) * 2013-05-21 2016-03-30 ARSANIS Biosciences GmbH Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
ES2811527T3 (es) * 2013-06-18 2021-03-12 Univ New York Composiciones farmacéuticas que contienen una leucocidina E mutada
RU2016119052A3 (en) * 2013-10-17 2018-09-10 Arsanis Biosciences Gmbh Cross-reactive Staphylococcus aureus antibody sequences
CA2932819A1 (en) * 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
AU2015303147A1 (en) * 2014-08-12 2017-02-23 Arsanis Biosciences Gmbh Predicting S. aureus disease
EP3283514A1 (en) * 2015-04-17 2018-02-21 ARSANIS Biosciences GmbH Anti-staphylococcus aureus antibody combination preparation
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
EP3638286A4 (en) * 2017-06-13 2021-03-10 Integrated Biotherapeutic Vaccines, Inc. IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
CN109384844B (zh) * 2017-08-04 2020-12-18 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用
KR102061735B1 (ko) * 2018-06-08 2020-01-02 대한민국(농림축산식품부 농림축산검역본부장) 황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물
WO2023213393A1 (en) * 2022-05-04 2023-11-09 Evaxion Biotech A/S Staphylococcal protein variants and truncates
CN116789813B (zh) * 2023-06-27 2024-04-26 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌α-溶血素的单克隆抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
KR20150043558A (ko) 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
CA2655133C (en) 2006-06-12 2018-03-20 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP2008013447A (ja) 2006-07-03 2008-01-24 Juntendo 毒素検出方法
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2284193A1 (en) 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
HRP20220068T1 (hr) 2010-05-05 2022-04-15 New York University Staphylococcus aureus leukocidini, terapijski pripravci, i njihova uporaba
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리

Also Published As

Publication number Publication date
WO2013156534A1 (en) 2013-10-24
PT2668208E (pt) 2015-10-12
HUE025378T2 (hu) 2016-02-29
RU2014145830A (ru) 2016-06-10
WO2013156534A9 (en) 2014-03-13
NZ700578A (en) 2017-03-31
DK2668208T3 (en) 2015-08-31
ZA201407330B (en) 2016-05-25
EP2668208A1 (en) 2013-12-04
US9914767B2 (en) 2018-03-13
CN104640878A (zh) 2015-05-20
US20150086539A1 (en) 2015-03-26
BR112014025299A2 (pt) 2013-10-24
CN104640878B (zh) 2018-12-04
IL235089B (en) 2019-03-31
JP2015515479A (ja) 2015-05-28
MX355985B (es) 2018-05-07
AU2013251165A1 (en) 2014-10-16
MX2014012501A (es) 2015-03-19
BR112014025299A8 (pt) 2018-01-16
CA2870223A1 (en) 2013-10-24
AU2013251165B2 (en) 2017-08-24
JP6228186B2 (ja) 2017-11-08
PL2668208T3 (pl) 2015-12-31
EP2668208B1 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
ES2546105T3 (es) Anticuerpo de reacción cruzada contra Staphylococcus aureus
CU20190109A7 (es) Moléculas de anticuerpo que se unen a cd73
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
CY1121349T1 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης
ECSP18007905A (es) Anticuerpos monoclonales contra bcma
TR201817932T4 (tr) Staphylococcus aureus alfa toksi̇ni̇ni̇ spesi̇fi̇k olarak bağlayan anti̇korlar ve kullanim yöntemleri̇
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
ES2664972T3 (es) Moléculas de unión anti-Psl de Pseudomonas y usos de las mismas
BR112016000903A2 (pt) anticorpos
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA201690314A1 (ru) Анти-garp-белок и его применения
CR20150329A (es) Inmunoglobulinas heterodiméricas
EA201690582A1 (ru) Модуляторы фактора в комплемента
CR20140585A (es) Proteinas de union a antigeno st2
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
CO6551674A2 (es) Anticuerpos anti-her3 y usos de los mismo
ECSP12012105A (es) Antídotos de Anticoagulantes
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
AR120515A2 (es) Conjugado de enzimas terapéuticas
BR112015008173A2 (pt) conjugados de pirrolobenzodiazepina-anticorpo anti-psma
BR112013025917A2 (pt) uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
BR112018005407A2 (pt) anticorpos que especificamente se ligam a tl1a.
EA201590412A1 (ru) Композиции антител и их применения